AbbVie Inc. (ABBV): Cost of Revenue
$18.20B
Year ended 2025-12-31
$18.36B
Trailing 12 months to 2026-06-30
+1.5%
3-year compound annual growth
+3.4%
5-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $18.20B | +7.7% | 2026-02-20, From 2025-01-01 |
| 2024-12-31 | $16.90B | -17.2% | 2026-02-20, From 2024-01-01 |
| 2023-12-31 | $20.41B | +17.2% | 2026-02-20, From 2023-01-01 |
| 2022-12-31 | $17.41B | -0.2% | 2025-02-14, From 2022-01-01 |
| 2021-12-31 | $17.45B | +13.4% | 2024-02-20, From 2021-01-01 |
| 2020-12-31 | $15.39B | +106.8% | 2023-02-17, From 2020-01-01 |
| 2019-12-31 | $7.44B | -3.6% | 2022-02-18, From 2019-01-01 |
| 2018-12-31 | $7.72B | +9.6% | 2021-02-19, From 2018-01-01 |
| 2017-12-31 | $7.04B | +20.7% | 2020-02-21, From 2017-01-01 |
| 2016-12-31 | $5.83B | n/a | 2019-02-27, From 2016-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| AbbVie Inc. (ABBV) | 2025-12-31 | $18.20B | +7.7% |
| Pfizer Inc (PFE) | 2025-12-31 | $16.07B | -10.0% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $16.38B | +7.8% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $11.05B | +31.3% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $13.94B | -0.2% |
| Abbott Laboratories (ABT) | 2025-12-31 | $19.32B | +3.3% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $30.26B | +10.1% |
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $8.32B | -1.9% |
| Viatris Inc (VTRS) | 2025-12-31 | $9.29B | +1.9% |
Compare ABBV, PFE, MRK, LLY side by side · Screen every company in Pharmaceutical Preparations ↗